Psoriasis
New tool uses clinical variables to predict psoriatic arthritis in patients with psoriasis
A new tool using readily available clinical variables to predict psoriatic arthritis risk in patients with psoriasis demonstrated reasonable accuracy and good model performance, according to data published in Arthritis & Rheumatology.
Study suggests somatic mutations do not cause, spread psoriasis
Published data from sequenced skin samples of 111 individuals with psoriasis suggest that the chronic condition is not started or spread by somatic mutations.
Nicotinamide riboside reduces inflammation in healthy controls, patients with psoriasis
Elevating nicotinamide adenine dinucleotide with nicotinamide riboside supplementation reduced inflammation in both healthy controls and patients with psoriasis, according to findings from a clinical study.
Zoryve achieves plaque psoriasis improvement in 95% of patients
New phase 3 study data showed Zoryve cream 0.3% provided measurable improvement in psoriasis severity in nearly all treated individuals, Arcutis announced in a press release.
Vtama cream 1% effective, safe for intertriginous plaque psoriasis treatment
New phase 4 study data showed Vtama cream 1% is effective and safe in the treatment of intertriginous plaque psoriasis in adults, Dermavant Sciences announced in a press release.
FDA approves Bimzelx for treatment of moderate to severe plaque psoriasis
The FDA has approved Bimzelx for moderate to severe plaque psoriasis treatment in adults who are eligible for systemic therapy or phototherapy, UCB announced in a press release.
Patient-reported outcomes favor roflumilast vs. vehicle in scalp, body psoriasis treatment
New results, including patient-reported outcome data, from the phase 3 ARRECTOR trial show roflumilast foam 0.3% continues to improve scalp and body psoriasis in adults, Arcutis announced in a press release.
FDA denies Stelara biosimilar application from Alvotech
The FDA has denied a biologics license application from Alvotech for its biosimilar to ustekinumab, citing “certain deficiencies” at the company’s facility in Reykjavik, Iceland, according to the manufacturer.
Data show Sotyktu maintains treatment outcomes for plaque psoriasis at 3 years
Three-year data from the POETYK PSO long-term extension trial of Sotyktu showed consistent efficacy and safety for the treatment of adults with moderate to severe plaque psoriasis, Bristol Myers Squibb announced in a press release.
Rapid clearance of generalized pustular psoriasis achieved with single imsidolimab dose
The phase 3 GEMINI-1 trial evaluating the safety and efficacy of imsidolimab for the treatment of patients with generalized pustular psoriasis flares met its primary endpoint, AnaptysBio announced in a press release.